OXB is a quality and innovation-led CDMO with over 25 years of experience, committed to helping our clients deliver cell and gene
therapies that transform patients’ lives. We offer end-to-end capabilities, from plasmid design and optimisation to clinical and commercial GMP manufacturing, accompanied by robust control systems, analytical methods and deep regulatory knowledge.

We have expertise in lentivirus, AAV, adenovirus, MVA vaccine and other viral vectors.

OXB operates out of 4 sites globally: Oxford UK (4 facilities), Bedford, US (1 facility), Lyon, France (1 facility), Strasbourg, France (2 facilities). We offer a vast number of technologies and services including a 4th Generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, perfusion process using process enhancers. OXB also offers Adenovirus and MVA vaccine production services and has process and assay development capabilities enabling delivery of projects from pre clinical to commercial stages. Additionally, we offer regulatory authoring and reviewing support for IND/IPMD, BLA/MAA submissions.